NOSIP overexpression promotes long-term persistence of CD8+ T cells during chronic infection - Report - MDSpire

NOSIP overexpression promotes long-term persistence of CD8+ T cells during chronic infection

  • By

  • Shihui Li

  • Toshikatsu Tamai

  • Yui Shinzawa

  • Sotaro Fujisawa

  • Yamato Tanabe

  • Makoto Utsunomiya

  • Hidetoshi Nakagawa

  • Junko Kurachi

  • Miki Koura

  • Eishiro Mizukoshi

  • Makoto Kurachi

  • June 22, 2026

  • 0 min

Share

Clinical Report: Enhanced Persistence of CD8+ T Cells through NOSIP Overexpression

Overview

This study demonstrates that overexpression of NOSIP enhances the persistence of antigen-specific CD8+ T cells during chronic antigen stimulation. NOSIP overexpression preserves a less differentiated T cell subset.

Background

Chronic antigen exposure leads to CD8+ T cell exhaustion, characterized by impaired function and increased apoptosis, which poses a significant challenge in managing chronic infections and tumors. Understanding mechanisms that sustain CD8+ T cell responses is crucial for developing effective immunotherapies. This study explores the role of NOSIP in promoting CD8+ T cell persistence.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

  • Overexpression of NOSIP enhances the persistence of antigen-specific CD8+ T cells under chronic antigen stimulation.
  • NOSIP overexpression preserves a less differentiated CX3CR1neg CD8+ T cell subset.
  • Inhibition of apoptosis in CD8+ T cells is associated with NOSIP overexpression.

Clinical Implications

The findings suggest that targeting NOSIP may enhance the durability of CD8+ T cell responses in chronic infections and tumors. This could inform the development of combination immunotherapy strategies aimed at sustaining T cell function.

Conclusion

NOSIP plays a role in maintaining CD8+ T cell persistence during chronic antigen exposure.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Author(s)/Org, Source, Year -- Title
  3. Author(s)/Org, Source, Year -- Title
  4. Author(s)/Org, Source, Year -- Title
  5. HIV/AIDS Treatment Guidelines | Clinicalinfo.HIV.gov
  6. Guidelines for the prevention,
  7. Twenty-four-week anti-PD-1 antibody regimen promoted HBsAg reduction and concurrently enhanced HBV-specific T cell responses in patients with chronic hepatitis B
  8. Study Details | NCT06885710 | HBV-Specific TCR-T Cell Therapy Combined With Nucleos(t)Ide Analogues in Chronic Hepatitis B Patients | ClinicalTrials.gov
  9. Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel | HIV | JAMA | JAMA Network
  10. HIV/AIDS Treatment Guidelines | Clinicalinfo.HIV.gov
  11. Guidelines for the prevention,
  12. Twenty-four-week anti-PD-1 antibody regimen promoted HBsAg reduction and concurrently enhanced HBV-specific T cell responses in patients with chronic hepatitis B
  13. Study Details | NCT06885710 | HBV-Specific TCR-T Cell Therapy Combined With Nucleos(t)Ide Analogues in Chronic Hepatitis B Patients | ClinicalTrials.gov
  14. Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel | HIV | JAMA | JAMA Network

Original Source(s)

Related Content